Skip to main content
Atrás
IMVT logo

Immunovant, Inc.

Calidad de datos: 100%
IMVT
NASDAQ Healthcare Biotechnology
$24.38
▲ $1.40 (6.09%)
Cap. Mercado: 4.96B
Rango del Día
$23.06 $24.67
Rango de 52 Semanas
$12.72 $29.25
Volumen
1,606,115
Promedio 50D / 200D
$26.10 / $20.79
Cierre Anterior
$22.98

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E -12.0 0.4
P/B 7.0 2.9
ROE % -62.5 3.7
Net Margin % 3.9
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$35.67 +46.3%
Low: $16.00 High: $50.00
EPS Futuro
-$2.63
Ingresos Est.
10 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $2.09
$2.09 – $2.09
1.3 B 11
FY2029 -$1.37
-$1.37 – -$1.37
460 M 8
FY2028 -$2.46
-$3.81 – -$1.47
110 M 13

Puntos Clave

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -376.63M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-62.46%
ROIC-46.44%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.00
Current Ratio11.16
Interest Coverage0.00

Valoración

P/E Ratio
-11.99
P/B Ratio7.01
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -413.84M
ROE -62.46% ROA -53.31%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -376.63M
ROIC -46.44% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 11.16
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -11.99 P/B Ratio 7.01
P/S Ratio N/A PEG Ratio -0.14
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 4.96B Enterprise Value 4.25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -413.84M -259.34M -210.96M -156.73M -107.43M
EPS (Diluted) -2.73 -1.88 -1.71 -1.43 -1.22
Gross Profit 0.0 0.0 0.0 0.0 0.0
Operating Income -438.15M -270.21M -208.28M -156.03M -108.12M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 776.22M 666.71M 405.84M 515.56M 412.49M
Total Liabilities 68.78M 48.96M 43.34M 45.74M 21.01M
Shareholders' Equity 707.45M 617.76M 362.49M 469.83M 391.48M
Total Debt 98,000.0 138,000.0 1.22M 2.36M 3.42M
Cash & Equivalents 713.97M 635.37M 376.53M 493.82M 400.15M
Current Assets 767.66M 665.77M 404.33M 512.93M 409.01M
Current Liabilities 68.78M 48.61M 43.30M 44.52M 18.77M